Trulicity Injection, Solution
Product Images NDC 50090-6453

Product Visual Gallery

This gallery contains 48 technical images submitted to the FDA as part of the official labeling for Trulicity (NDC 50090-6453). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl500906453)

TRULICITY 0.75 mg/0.5 mL injection label from A-S Medication Solutions. The label includes the proprietary name TRULICITY, generic name Dulaglutide Injection, dosage strength 0.75 mg/0.5 mL, and instructions to protect from light, store in original container, and not freeze. It specifies single-dose pens and single-use only with the subcutaneous route.*

FDA Label Image

Logo (Logo)

FDA Label Image

Qr Code (Qr V1)

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Back V1)

Illustration showing the injection sites for a subcutaneous injection, highlighting the upper outer arm areas on both arms. The diagram indicates suitable locations for administering an injection such as dulaglutide.*

FDA Label Image

Figure (Trulicity Ifu 0point75 Injection Sites Front V1)

An anatomical illustration showing preferred subcutaneous injection sites on a human body. Highlighted areas in yellow include the abdomen around the navel and the front and outer sides of both thighs, indicating typical injection locations for subcutaneous delivery.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Back V1)

An anatomical illustration showing a human figure from the back with blue highlight areas on both upper arms, indicating recommended injection sites for subcutaneous administration.*

FDA Label Image

Figure (Trulicity Ifu 1point5 Injection Sites Front V1)

An anatomical illustration highlighting appropriate injection sites for a subcutaneous injection. The areas marked in blue include the abdomen around the navel and the front middle thigh regions on both legs. This visual guide indicates where to administer the injection.*

FDA Label Image

Figure (Trulicity Ifu 3mg Injection Sites V1)

An instructional diagram showing recommended subcutaneous injection sites on a human body. The front view highlights areas on the abdomen, upper outer arms, and front thighs. The back view highlights areas on the upper outer arms and back thighs. The figure is intended to guide patients administering injections.*

FDA Label Image

Figure (Trulicity Ifu 4point5mg Injection Sites V1)

Illustration showing recommended subcutaneous injection sites for TRULICITY (dulaglutide). Sites highlighted in green include the outer upper arms, abdomen, and front and outer sides of the thighs, indicating appropriate locations for injection administration.*

FDA Label Image

Figure (Trulicity Ifu Check V1)

FDA Label Image

Exclamation (Trulicity Ifu Exclamation V1)

The image shows a vial vial holding a solution injection of TRULICITY (Dulaglutide) at a strength of 0.75 mg/0.5 mL. The packaging indicates it is for subcutaneous use and is labeled by A-S Medication Solutions. The product is identified as a human prescription drug.*

FDA Label Image

Figure (Trulicity Ifu Expiration Location V2)

An instructional illustration indicating the location of the expiration date on a TRULICITY injection pen. The image shows a side view of the pen with a red arrow pointing to a black rectangular area near the middle of the device, labeled as the expiration date position.*

FDA Label Image

Figure (Trulicity Ifu Inspect V1)

FDA Label Image

Locked (Trulicity Ifu Locked V1)

The image shows a TRULICITY injection solution package containing Dulaglutide, 0.75 mg per 0.5 mL dosage form. It is labeled for subcutaneous use and manufactured by A-S Medication Solutions. The package also displays the product NDC 50090-6453 and indicates it is a human prescription drug.*

FDA Label Image

Figure (Trulicity Ifu Prepare V1)

FDA Label Image

Figure (Trulicity Ifu Remove V1)

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F2 V3)

Illustration showing a hand holding a TRULICITY (Dulaglutide) injection pen, with the other hand removing a black cap from the pen. The diagram includes arrows indicating the direction of cap removal, intended as part of the injection preparation instructions.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F3 V3)

An instructional illustration showing hands preparing a prefilled syringe by removing a green cap, demonstrating part of the injection process for a subcutaneous injectable medication.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F4 V3)

An instructional illustration demonstrating the use of an injection device. It shows hands holding a pen-like injector at an angle with a 5-10 second timer symbol, indicating a recommended waiting time during injection. An enlarged inset highlights a dial or indicator on the injector tip to emphasize correct technique or dosage setting.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 F5 V3)

An illustration showing a hand holding a prefilled syringe, positioned above a biohazard sharps disposal container for safe injection needle disposal. The syringe has a purple label. The image demonstrates proper disposal procedure for injection devices.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen Parts V3)

An instructional diagram of the TRULICITY injection pen showing labeled parts including the injection button at the top, lock ring and lock/unlock indicator near the upper body, medicine reservoir inside the pen, clear base, and the base cap at the needle end.*

FDA Label Image

Figure (Trulicity Ifu Sup 0point75 Pen V3)

TRULICITY 0.75 mg/0.5 mL injection, solution in a single-use subcutaneous prefilled pen syringe. The pen features a white body with a purple and yellow label wrap and a green cap. The labeler is A-S Medication Solutions, identified by the visible logo on the pen's label.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F2 V3)

Illustration showing a hand holding a TRULICITY injection pen solution with the other hand removing or attaching a black protective cap at the bottom of the pen, accompanied by a downward arrow indicating the direction of movement.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F3 V3)

An instructional illustration showing the proper technique for using a TRULICITY (Dulaglutide) injection pen. The image depicts hands preparing or administering a subcutaneous injection, indicating how to handle the pen before injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F4 V3)

An instructional diagram showing a person holding an injection device, demonstrating the preparation or injection process. A close-up inset highlights a specific part of the injector with an arrow and circle, emphasizing a detail of the device. Text indicates holding the device for 5-10 seconds during use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 F5 V3)

An instructional illustration showing a hand holding a syringe above a biohazard sharps disposal container, demonstrating safe disposal of the syringe after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen Parts V3)

Illustration showing the parts of a TRULICITY (Dulaglutide) injection pen, 0.75 mg/0.5 mL dose. Labeled components include the injection button, lock ring, indicator with lock/unlock symbols, medicine chamber, clear base, and base cap, helping users identify each part of the subcutaneous injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 1point5 Pen V3)

TRULICITY 0.75 mg/0.5 mL injection, solution in a prefilled pen device for subcutaneous administration. The pen features a clear window for viewing the solution, a purple, white, and blue body, and a green activation button at the end. Labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F2 V1)

An instructional diagram showing a hand holding a TRULICITY (Dulaglutide) injection pen with another hand turning or removing the black cap at the pen's end, indicated by a downward arrow. The illustration likely demonstrates part of the preparation or activation process for the subcutaneous injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F3 V1)

An instructional illustration showing the hands of a person preparing a subcutaneous injection using a TRULICITY (dulaglutide) single-dose pen. The image highlights twisting or removing the cap from the pen in preparation for injection.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F4 V1)

An instructional illustration depicting the use of an injection pen for TRULICITY (Dulaglutide) 0.75 mg/0.5 mL subcutaneous injection. It shows hands administering the injection with a focus on pressing the plunger and indicates a waiting time of 5-10 seconds. A close-up highlights the gray plunger, noting the injection is complete when the gray plunger is visible.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg F5 V1)

An instructional illustration showing a hand holding a syringe with a purple cap above a biohazard sharps container, indicating proper disposal of the syringe after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen Parts V1)

Illustration of a TRULICITY (dulaglutide) injection pen showing labeled parts including the Injection Button, Lock Ring, Indicator, Lock/Unlock icon, Medicine section, Clear Base, and Base Cap, indicating the top and bottom (needle end) orientation.*

FDA Label Image

Figure (Trulicity Ifu Sup 3mg Pen V1)

TRULICITY 0.75 mg/0.5 mL injection, solution in a subcutaneous single-dose pen injector. The device is white with green, purple, and red labeling accents, featuring a clear window and a protective cap. Labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F2 V1)

An instructional diagram showing two hands preparing a TRULICITY injection pen. One hand holds the pen upright while the other hand is removing a black cap or protective cover from the base of the pen. A downward arrow indicates the direction to pull off the cap. The pen has a green top and a purple label band.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F3 V1)

An instructional illustration showing a person administering a subcutaneous injection using a prefilled pen injector. The image depicts the hand rotating the green cap on the pen before injection into the thigh, with a focus on proper handling technique.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F4 V1)

An instructional illustration showing a person preparing a subcutaneous injection with a pen device. It highlights the timing for injection (5-10 seconds) and indicates completion by the visibility of the gray plunger. The diagram includes a close-up of the injection device's plunger marker.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 F5 V1)

Illustration showing a hand holding a TRULICITY (dulaglutide) single-use prefilled injection pen above a biohazard sharps disposal container, demonstrating proper disposal of the injection device after use.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen Parts V1)

An instructional diagram of a TRULICITY injection pen showing labeled parts including the injection button at the top, lock ring, indicator, lock/unlock symbols, medicine visible inside the pen, clear base, base cap, and the bottom needle end. The diagram highlights the functional components of the subcutaneous injection device.*

FDA Label Image

Figure (Trulicity Ifu Sup 4point5 Pen V1)

TRULICITY 0.75 mg/0.5 mL injection, solution in a single-dose prefilled subcutaneous injection pen. The pen features a clear barrel with a purple and green label and a green cap, labeled by A-S Medication Solutions.*

FDA Label Image

Figure (Trulicity Ifu Unfold V1)

An instructional diagram showing a folded paper with arrows indicating to unfold and lay flat. Text instructs to read both sides for full instructions.*

FDA Label Image

Unlocked (Trulicity Ifu Unlock V1)

TRULICITY 0.75 mg/0.5 mL injection, solution for subcutaneous use. The label shows the product name, active ingredient Dulaglutide, dosage form, and strength. The labeler is A-S Medication Solutions.*

FDA Label Image

Figure 1 (Trulicity Pi F1 V2)

A figure showing the pharmacokinetic ratio and 90% confidence intervals of Dulaglutide exposure metrics (AUC and Cmax) relative to reference values. The chart compares intrinsic factors such as weight, age, sex, and race, as well as renal and hepatic impairment severity on drug exposure ratios, with a horizontal axis labeled 'Ratio Relative to Reference' ranging from 0.0 to 2.0.*

FDA Label Image

Figure 2 (Trulicity Pi F2 V2)

A forest plot chart showing the pharmacokinetic (PK) ratios and 90% confidence intervals for various coadministered drugs compared to a reference. It lists drugs such as Lisinopril, Metoprolol, Digoxin, Norelgestromin, Ethinylestradiol, Atorvastatin, Metformin, Acetaminophen, S-Warfarin, R-Warfarin, and Sitagliptin, with AUC and Cmax values plotted along a ratio scale from 0.0 to 2.0 relative to the reference.*

FDA Label Image

Figure 3 (Trulicity Pi F3 V3)

A line graph showing least squares mean HbA1c (%) over 52 weeks post-randomization for TRULICITY 1.5 mg, TRULICITY 0.75 mg, Sitagliptin 100 mg, and placebo groups. The x-axis represents time in weeks, and the y-axis measures HbA1c percentage. The graph compares the effects of these treatments on HbA1c levels over time.*

FDA Label Image

Figure 4 (Trulicity Pi F4 V3)

A line graph depicting mean HbA1c (%) over weeks post-randomization for TRULICITY at doses of 1.5 mg, 3 mg, and 4.5 mg. The x-axis shows weeks post-randomization, and the y-axis shows mean HbA1c percentage, illustrating changes in levels across three dose groups over time up to week 36.*

FDA Label Image

Figure 5 (Trulicity Pi F5 V2)

Line graph showing the effect of TRULICITY (dulaglutide) 0.75 mg and 1.5 mg, exenatide, and placebo on LS Mean HbA1c (%) over 26 weeks post-randomization. The graph plots HbA1c levels at baseline, week 13, and week 26, illustrating changes across treatment groups.*

FDA Label Image

Figure 6 (Trulicity Pi F6 V2)

A Kaplan-Meier curve comparing the percentage of patients with an event over time (up to 6 years) between Dulaglutide and placebo groups. The vertical axis shows patients with an event (%) and the horizontal axis shows time from randomization in years. The Dulaglutide group exhibits a slightly lower percentage of events than the placebo group. A hazard ratio (HR) of 0.88 with 95% confidence interval [0.79, 0.99] is noted.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.